Subscribe To

Price Alert Latest News Economic Calendar News

MGNX / MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET. Read More

Demo Live Account See Partner Details

Content Topics

Macrogenics

Announces

Date

Fourth

Quarter

2022

Financial

Results

Conference

Stock

MGNX

Posted: Mar 7 2023, 18:00

Author Name: GlobeNewsWire

MGNX News

By Zacks Investment Research
August 14, 2023

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered

By The Motley Fool
August 10, 2023

Why Shares of MacroGenics Are Jumping Thursday

MacroGenics saw a big jump in net income. It receives royalties from Sanofi for breast cancer drug Tzield.

By Seeking Alpha
August 9, 2023

MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jim Karrels - VP and CFO Scott Koenig

By GlobeNewsWire
July 31, 2023

MacroGenics Announces Date of Second Quarter 2023 Financial Results Conference Call

ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing an

By Seeking Alpha
May 29, 2023

MacroGenics: Non-Dilutive Funding Propels Drug Candidates (Rating Upgrade)

MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growt

By Zacks Investment Research
May 9, 2023

MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates

MacroGenics (MGNX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $1.07. This compares to loss of $1.08 per

By GlobeNewsWire
April 24, 2023

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializ

By The Motley Fool
March 20, 2023

Why MacroGenics Stock Inched Higher on Monday

Two analysts raised their price targets on the cancer-focused biotech. They are the latest prognosticators to adjust their takes on the company follow

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.